The recent publication of two controlled trials on boceprevir and three on telaprevir heralds a new era for hepatitis C therapy. Bocreprevir and telaprevir are protease inhibitors which act directly on the hepatitis C virus to inhibit replication and are referred to as direct acting antiviral agents (DAA’s). They are the first 2 such agents to be licensed but it is hoped that many more will soon follow. These are very important studies and represent a major advance in treatment for patients with chronic hepatitis C virus infection. To appreciate their significance it is important to be aware of some of the clinical features of hepatitis C virus infection. Firstly, hepatitis C exposure leads to chronic infection in approximately 70% of patie...
It has been estimated that between 1.5 and 2 million people in Italy have anti-HCV antibodies. The v...
Background: Hepatitis C is a disease with significant global impact. According to the World Health O...
Background The nonstructural 3 serine protease inhibitors (PIs), boceprevir and telaprevir, represen...
The recent publication of two controlled trials on boceprevir and three on telaprevir heralds a new ...
Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapi...
Item does not contain fulltextHepatitis C virus (HCV) is the most common infectious cause of chronic...
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepat...
Hepatitis C virus (HCV) infection im-poses a significant global health burden, with an estimated 170...
Abstract The development of protease inhibitors (PIs) such as telaprevir and boceprevir constitutes ...
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepat...
Chronic hepatitis C virus (HCV) infection, a blood-borne virus, is the leading cause of chronic live...
The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a st...
Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a ma...
Anno 2015, the race for developing the ideal therapy, or what is now called "cure," for hepatitis C ...
The pegylated interferon regimen has long been the lone effective management of chronic hepatitis C ...
It has been estimated that between 1.5 and 2 million people in Italy have anti-HCV antibodies. The v...
Background: Hepatitis C is a disease with significant global impact. According to the World Health O...
Background The nonstructural 3 serine protease inhibitors (PIs), boceprevir and telaprevir, represen...
The recent publication of two controlled trials on boceprevir and three on telaprevir heralds a new ...
Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapi...
Item does not contain fulltextHepatitis C virus (HCV) is the most common infectious cause of chronic...
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepat...
Hepatitis C virus (HCV) infection im-poses a significant global health burden, with an estimated 170...
Abstract The development of protease inhibitors (PIs) such as telaprevir and boceprevir constitutes ...
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepat...
Chronic hepatitis C virus (HCV) infection, a blood-borne virus, is the leading cause of chronic live...
The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a st...
Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a ma...
Anno 2015, the race for developing the ideal therapy, or what is now called "cure," for hepatitis C ...
The pegylated interferon regimen has long been the lone effective management of chronic hepatitis C ...
It has been estimated that between 1.5 and 2 million people in Italy have anti-HCV antibodies. The v...
Background: Hepatitis C is a disease with significant global impact. According to the World Health O...
Background The nonstructural 3 serine protease inhibitors (PIs), boceprevir and telaprevir, represen...